サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1178007

乾癬性関節炎治療薬の世界市場：業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Psoriatic Arthritis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
乾癬性関節炎治療薬の世界市場：業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年11月08日
発行: Transparency Market Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の乾癬性関節炎治療薬市場について調査分析し、市場の促進要因や抑制要因、機会、主な考察、セグメント別の分析と予測、地域別分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の乾癬性関節炎治療薬市場

第4章 市場概要

  • イントロダクション
    • セグメントの定義
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の乾癬性関節炎治療薬市場の分析と予測（2017年～2031年）
    • 市場収益予測
    • 市場規模・出荷台数予測
  • ポーターのファイブフォース分析

第5章 主な考察

  • 世界の主要国における疾患の有病率・発症率
  • パイプライン分析
  • 主な合併と買収
  • COVID-19の影響分析

第6章 世界の乾癬性関節炎治療薬市場の分析と予測：医薬品クラス別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：医薬品クラス別（2017年～2031年）
    • TNF阻害薬
    • インターロイキン阻害薬
    • PDE4阻害薬
    • その他
  • 市場の魅力度分析：医薬品クラス別

第7章 世界の乾癬性関節炎治療薬市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：投与経路別（2017年～2031年）
    • 経口
    • 非経口
    • 局所
  • 市場の魅力度分析：投与経路別

第8章 世界の乾癬性関節炎治療薬市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：流通チャネル別（2017年～2031年）
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力度分析：流通チャネル別

第9章 世界の乾癬性関節炎治療薬市場の分析と予測：地域別

  • 主な調査結果
  • 市場価値予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力度分析：地域別

第10章 北米の乾癬性関節炎治療薬市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測（2017年～2031年）：医薬品クラス別
    • TNF阻害薬
    • インターロイキン阻害薬
    • PDE4阻害薬
    • その他
  • 市場価値予測（2017年～2031年）：投与経路別
    • 経口
    • 非経口
    • 局所
  • 市場価値予測（2017年～2031年）：流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国別（2017年～2031年）
    • 米国
    • カナダ
  • 市場の魅力度分析
    • 医薬品クラス別
    • 投与経路別
    • 流通チャネル別
    • 国別

第11章 欧州の乾癬性関節炎治療薬市場の分析と予測

第12章 アジア太平洋地域の乾癬性関節炎治療薬市場の分析と予測

第13章 ラテンアメリカの乾癬性関節炎治療薬市場の分析と予測

第14章 中東・アフリカの乾癬性関節炎治療薬市場の分析と予測

第15章 競合情勢

  • 市場参入企業 - 競合マトリックス（企業の階層と規模別）
  • 市場シェア分析：企業別（2021年）
  • 企業プロファイル
    • AbbVie, Inc.
    • Janssen Pharmaceutical NV
    • Novartis AG
    • Amgen, Inc.
    • Celgene Corporation
    • Eli Lilly and Company
    • UCB SA
    • Bristol Myers Squibb
    • その他の有名企業
図表

List of Tables

  • Table 01: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Psoriatic Arthritis Therapeutics Market Snapshot
  • Figure 02: Global Psoriatic Arthritis Therapeutics Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031
  • Figure 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 05: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration (2021)
  • Figure 06: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2021)
  • Figure 04: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class (2021)
  • Figure 07: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Region (2021)
  • Figure 08: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 09: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 10: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2021-2031
  • Figure 11: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2021-2031
  • Figure 12: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2021-2031
  • Figure 13: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021-2031
  • Figure 14: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 15: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 16: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2021-2031
  • Figure 17: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2021-2031
  • Figure 18: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2021-2031
  • Figure 19: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2031
  • Figure 20: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2021-2031
  • Figure 21: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2021-2031
  • Figure 22: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2021-2031
  • Figure 23: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 24: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region, 2017 and 2031
  • Figure 25: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 26: North America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 27: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country, 2017 and 2031
  • Figure 28: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 29: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 30: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 31: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 32: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 33: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 34: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 35: Europe Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 36: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 37: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 38: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 39: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 40: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 41: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 42: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 43: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 44: Asia Pacific Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 45: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 46: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 47: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 48: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 49: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 50: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 51: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 52: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 53: Latin America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 54: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 55: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 56: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 57: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 58: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 59: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 60: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 61: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 62: Middle East & Africa Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021-2031
  • Figure 63: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 64: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 65: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031
  • Figure 66: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by drug Class, 2022-2031
  • Figure 67: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031
  • Figure 68: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 69: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031
  • Figure 70: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 71: Global Psoriatic Arthritis Therapeutics Market Share Analysis, by Company (2021)
目次
Product Code: TMRGL61917

TMR's report on the global psoriatic arthritis therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global psoriatic arthritis therapeutics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global psoriatic arthritis therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the psoriatic arthritis therapeutics market.

The report delves into the competitive landscape of the global psoriatic arthritis therapeutics market. Key players operating in the global psoriatic arthritis therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global psoriatic arthritis therapeutics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriatic Arthritis Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Pipeline Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. Covid-19 Impact Analysis

6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. TNF Inhibitors
    • 6.3.2. Interleukin Inhibitors
    • 6.3.3. PDE4 Inhibitors
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. TNF Inhibitors
    • 10.2.2. Interleukin Inhibitors
    • 10.2.3. PDE4 Inhibitors
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. TNF Inhibitors
    • 11.2.2. Interleukin Inhibitors
    • 11.2.3. PDE4 Inhibitors
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
    • 11.3.3. Topical
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. TNF Inhibitors
    • 12.2.2. Interleukin Inhibitors
    • 12.2.3. PDE4 Inhibitors
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
    • 12.3.3. Topical
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. TNF Inhibitors
    • 13.2.2. Interleukin Inhibitors
    • 13.2.3. PDE4 Inhibitors
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
    • 13.3.3. Topical
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. TNF Inhibitors
    • 14.2.2. Interleukin Inhibitors
    • 14.2.3. PDE4 Inhibitors
    • 14.2.4. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
    • 14.3.3. Topical
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. AbbVie, Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Janssen Pharmaceutical NV
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Amgen, Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Celgene Corporation
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Eli Lilly and Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. UCB S.A
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bristol Myers Squibb
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Other Prominent Players